AAM Condemns ‘Build Back Better 2.0’ Due To Off-Patent Impact

US Draft Drug Legislation Could Complicate Market Entry For Generics And Biosimilars

 
• By Chloe Kent

The Association for Accessible Medicines has criticized draft legislation regarding US drug pricing negotiations for the impact proposed new laws could have on generic and biosimilar drugs.

Senator Joe Manchin is confronted by climate activists leaving his boat on his way to Capitol Hill
Build Back Better crumbled last year after Joe Manchin refused to vote for the legislation • Source: Shutterstock

More from Policy & Regulation

More from Generics Bulletin